B-hSIRPα mice

Basic Information

Description

SIRPα (Signal-regulatory protein alpha) is a transmembrane protein widely expressed in myeloid cells, stem cells and neurons. Its extracellular part includes 3 Immunoglobulin like domains. SIRPα binds to its ligand CD47 through the variable IgV-like domains. CD47 is also widely expressed in multiple tissue cells. CD47+ cells activate SIRPα on macrophage surface, and such interaction can prevent phagocytosis. Previous studies reveal that the interruption of SIRPα-CD47 interaction substantially inhibits a variety of tumors. SIRPα/CD47 antibodies are considered as the next star immunotherapy following PD1/PD-L1 antibodies.

Targeting Strategy

Details

Phenotype

Protein Expression Analysis

 

Abdominal cells from both wild type (WT) C57BL/6 and homozygous B-hSIRPα mice were analyzed by flow cytometry. Mouse SIRPα + cells were detectable in non-T and non-B cells from both WT C57BL/6 and the homozygous B-hSIRPα mice, while human SIRPα+ cells were only detectable in non-T and non-B cells from the homozygous B-hSIRPα mice. This might be resulted from the cross recognition of hSIRPα by anti-mSIRPα antibody.

Application

Human SIRPα mAb Efficacy Evaluation (MC38-hCD47 Cells)

Murine colon cancer MC38-hCD47 cells (without mCD47 cells) were subcutaneously implanted into homozygous B-hSIRPα mice. Mice were grouped when the tumor size was approximately 150±50 mm³ (n=5). Three human SIRPα antibodies differently inhibited tumor growth, confirming that the B-hSIRPα mouse model is a powerful tool for in vivo SIRPα antibody pharmacological efficacy study. (A) Tumor average volume ± SEM, (B) Mice average weight ± SEM.

Human SIRPA mAb efficacy evaluation (MC38-hCD47 cells)

Murine colon cancer MC38-hCD47 cells (without mCD47 cells) were subcutaneously implanted into homozygous B-hSIRPA mice. Mice were grouped when the tumor size was approximately 150±50mm3 (n=5). Human SIRPA antibodies differently inhibited tumor growth, confirming that the B-hSIRPA mouse model is a powerful tool for in vivo SIRPA antibody pharmacological efficacy study. (A) Tumor average volume ± SEM, (B) Mice average weight ± SEM.

References

1. Genes Cells. 2015 Jun;20(6):451-63. doi: 10.1111/gtc.12238. Epub 2015 Mar 27.
2. Nat Immunol. 2007 Dec;8(12):1287-9.
3. Blood. 2013 Feb 21;121(8):1316-25. doi: 10.1182/blood-2012-06-440354. Epub 2013 Jan 4.
4. Nat Immunol. 2007 Dec;8(12):1313-23. Epub 2007 Nov 4.